Lancing: <i>Quo Vadis?</i>

Heinemann, Lutz; Boecker, Dirk

doi:10.1177/193229681100500420

Cited by 23 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…People with diabetes are asked to perform SMBG, manage multiple medications, maintain foot hygiene, adhere to diet and meal plans, and engage in exercise programs [9]. While for some insulin users SMBG is an important component of diabetes care, it poses a significant inconvenience/burden on the patient, in addition to the significant and well-documented economic costs [10–13]. …”

Section: Introductionmentioning

confidence: 99%

Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes

et al. 2012

View full text Add to dashboard Cite

IntroductionPeople with diabetes are at a higher risk of developing a variety of medical conditions relative to those without diabetes, resulting in increased healthcare costs. Self-monitoring of blood glucose (SMBG) is accepted as a recommended element of effective diabetes self-management. However, little is known about the real-world frequency and actual expenditures associated with SMBG, as well as the impact of SMBG costs relative to the cost of diabetes treatments. The primary objective is to evaluate the real-world utilization and costs of SMBG tests in Canada among insulin-treated diabetes patients during a 12-month follow-up period.MethodsA retrospective cohort study was conducted using the IMS Brogan Inc. Drug Plan database from July 1, 2006 through June 30, 2010. Total costs during the 12-month follow-up period were assessed, focusing on blood glucose (BG) testing strip costs, insulin therapy costs, and costs associated with oral antidiabetics medications. All prevalent patients with two or more prescriptions for insulin between January 1, 2007 and December 31, 2009 were initially included in the analysis, the first prescription serving as their index date. Depending on the insulin type(s) used, patients were subcategorized into one of four insulin regimen groups (basal, bolus, premix, or basal–bolus).ResultsAmong an initial sample of patients with two or more claims for insulin between January 1, 2007 and December 31, 2009, 142,551 met the aforementioned inclusion and exclusion criteria. An overall mean utilization of pharmacy-based blood glucose testing of approximately 1,094 strips per person per year was observed, with an average cost per testing strip of Canadian $0.79. SMBG treatment costs for insulin users ($860), specifically those associated with prescription testing strips, totaled 41.6% of the average annual pharmacy costs of diabetes-related prescriptions ($2,068).ConclusionThis study shows that SMBG accounts for approximately 40% of the total diabetes-related pharmacy costs for insulin users.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Significant technological improvements have been made in the field of lancing fingertips or alternative sites for obtaining a blood sample to address key customer needs, including better performance (regarding pain, wound healing, and long-term sensitivity), reduced costs, and higher integration with other components of blood glucose monitoring (e.g. integration of the lancing device with the glucose monitor) [70]. Bruttomesso Technological advancement in treatment of T1DM suggests that mobile diabetes management systems may represent a strategy to improve the quality of diabetes care.…”

Section: Recent Technological Advancements In Self-monitoring Blood Gmentioning

confidence: 99%

Self-Monitoring in Diabetes: When and How Much?

Pintaudi¹,

Nicolucci²

2014

Frontiers in Diabetes

View full text Add to dashboard Cite

Self-monitoring of blood glucose (SMBG) is an integral component of diabetes care for patients with type 1 diabetes mellitus (T1DM). It is an essential tool for the improvement of glycemic control and to increase patient empowerment and adherence to treatment. The standard recommended frequency of SMBG in T1DM is 3-4 times daily, even though many patients might require more frequent monitoring in special conditions. The frequency of testing should be agreed upon by the patients and their healthcare teams. As a general rule, more blood glucose tests are needed as the therapy becomes more intensive. People using insulin pump therapy should perform SMBG at least 4-6 times daily, and especially during establishment of pump therapy. To confirm hypoglycemia, patients must perform SMBG and repeat it every 15 min until euglycemia. Patients undergoing frequent asymptomatic hypoglycemia should perform SMBG more often. During intercurrent illness, patients need to monitor their blood glucose levels at least every 4 h, or every 2 h when blood glucose levels keep rising, to avoid diabetic ketoacidosis. With physical activity, patients should perform SMBG before, during, and after exercise. While driving, SMBG should be performed before leaving and at 2-hour intervals during long journeys. The issue of SMBG in women with T1DM deserves specific attention, especially during the menstrual period, preconception time, pregnancy (at least 7 tests/day), and breastfeeding.Between 1964 and 1967, a new method for measuring glucose, Dextrostix, was introduced. Based on finger puncture with a lancet or with an injection needle, these strips extemporaneously determined capillary blood glucose, and provided an alternative for the sticks that determined urinary glucose. The test was performed by putting a thick drop of blood on the stick, washing it under water for the elimination of other blood constituents, and then comparing it, after 1 min of reaction, with a color scale ranging from light yellow to darker colors, depending on the amount of glu-

show abstract

“…This step requires the use of piercing device to perform an invasive act into a finger or another part of the body. Although only a very small amount of blood is required, the pain and psychological barrier of piercing are the main causes of the failure of general DM patients to fail to perform SMBG as frequently as required by their doctors [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…For example, when sampling blood from babies with thin skin, the depth of piercing depth of the lancet on can be adjusted to reduce the pain caused [8][9][10]. (4) Change the mechanical design of the lancing device to reduce the vibration of the lancet to cause a smaller Appl. Sci.…”

Section: Introductionmentioning

confidence: 99%

Characterization and Clinical Trial of an Innovative High-Speed Lancing Device

Chang

Yeh

Lee³

et al. 2016

Applied Sciences

View full text Add to dashboard Cite

An innovative high-speed lancing device has a lancet that moves so fast that it is not affected at all by the vibration of its spring, and does not pierce the skin repeatedly, greatly reducing the pain that is caused to diabetes mellitus (DM) patients during blood sampling. As revealed by experimental measurements of the acceleration of a lancet using an accelerometer, the lancet pierces the skin only once. The maximum acceleration and the instant piercing velocity of the lancet are 9.4 times and 1.78 times those of a conventional lancing device, respectively. Meanwhile, the period for which the lancet remains in the skin is 0.014 s shorter than that of the conventional lancing device. A clinical trial that involved 100 participants yielded statistical results concerning the numeric rating of pain scale (NRS) of pain intensity, which is internationally recognized as the pain with the highest validity, that showed that the NRS of participants who used the innovative high-speed lancing device was 2.65 less than that of those who used the conventional lancing device, and the duration of the pain after blood sampling was 76.1 min shorter.

show abstract

Lancing: Quo Vadis?

Cited by 23 publications

References 22 publications

Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes

Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes

Self-Monitoring in Diabetes: When and How Much?

Characterization and Clinical Trial of an Innovative High-Speed Lancing Device

Contact Info

Product

Resources

About